Related references
Note: Only part of the references are listed.Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2016)
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
Heather L. Gelhorn et al.
CLINICAL THERAPEUTICS (2016)
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study
Philippe Ruszniewski et al.
DIGESTIVE AND LIVER DISEASE (2016)
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Aaron I. Vinik et al.
ENDOCRINE PRACTICE (2016)
Association between general self-efficacy, social support, cancer-related stress and physical health-related quality of life: a path model study in patients with neuroendocrine tumors
Trude Haugland et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden
Timothy P. Pearman et al.
SUPPORTIVE CARE IN CANCER (2016)
Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
Fabio Efficace et al.
CANCER (2015)
Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making
Jonathan R. Rees et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Quality of life after treatment of neuroendocrine liver metastasis
Gaya Spolverato et al.
JOURNAL OF SURGICAL RESEARCH (2015)
Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review
Michael A. Feuerstein et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
O. Bylicki et al.
ANNALS OF ONCOLOGY (2015)
The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review
Linda Dirven et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial
Emmanuel Mitry et al.
EUROPEAN JOURNAL OF CANCER (2014)
Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making
Fabio Efficace et al.
EUROPEAN JOURNAL OF CANCER (2014)
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours
Tim Meyer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical Decision Making
Fabio Efficace et al.
EUROPEAN UROLOGY (2014)
Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry
Fabio Efficace et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Bryce B. Reeve et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
Ebrahim S. Delpassand et al.
PANCREAS (2014)
Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers
Melanie Calvert et al.
PLOS ONE (2014)
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
Marta Martin-Richard et al.
BMC CANCER (2013)
Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours
G. Yadegarfar et al.
BRITISH JOURNAL OF CANCER (2013)
Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
S. Vinjamuri et al.
BRITISH JOURNAL OF CANCER (2013)
The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice
Melanie Calvert et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2013)
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards
Michael Brundage et al.
QUALITY OF LIFE RESEARCH (2013)
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
Bryce B. Reeve et al.
QUALITY OF LIFE RESEARCH (2013)
Fear of Cancer Recurrence after Curative Pancreatectomy: A Cross-sectional Study in Survivors of Pancreatic and Periampullary Tumors
Maria Q. B. Petzel et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
Larry K. Kvols et al.
ENDOCRINE-RELATED CANCER (2012)
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John K. Ramage et al.
GUT (2012)
A Guide to Interpreting a Study of Patient-Reported Outcomes
Erika Davis Sears et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2012)
Comparison of Health-Related Quality of Life in Patients With Neuroendocrine Tumors With Quality of Life in the General US Population
Jennifer L. Beaumont et al.
PANCREAS (2012)
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
Saima Khan et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers
Michael Brundage et al.
QUALITY OF LIFE RESEARCH (2011)
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
J. B. Cwikla et al.
ANNALS OF ONCOLOGY (2010)
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008
David Cella et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2010)
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
David L. Bushnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Selective Internal Radiotherapy with Yttrium-90 Microspheres for Hepatic Metastatic Neuroendocrine Tumors: A Prospective Single Center Study
Marc Kalinowski et al.
DIGESTION (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours
Anouk N. A. van der Horst-Schrivers et al.
NEUROENDOCRINOLOGY (2009)
Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors
Catharina M. Korse et al.
NEUROENDOCRINOLOGY (2009)
Development of the Norfolk Quality of Life Tool for Assessing Patients With Neuroendocrine Tumors
Etta Vinik et al.
PANCREAS (2009)
The applications of PROs in clinical practice: what are they, do they work, and why?
Joanne Greenhalgh
QUALITY OF LIFE RESEARCH (2009)
Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population
Trude Haugland et al.
QUALITY OF LIFE RESEARCH (2009)
Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas
Raffaele Pezzilli et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Is satisfaction with doctors' care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report
Camilla Frojd et al.
SCANDINAVIAN JOURNAL OF CARING SCIENCES (2009)
Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life
G. Larsson et al.
EUROPEAN JOURNAL OF CANCER CARE (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Are importance-satisfaction discrepancies with regard to ratings of specific health-related quality-of-life aspects valid indicators of disease- and treatment-related distress among patients with endocrine gastrointestinal tumours?
G. Larsson et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Measuring quality of life in cosmetic and Reconstructive breast surgery: A systematic review of patient-reported outcomes instruments
Andrea L. Pusic et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2007)
Health related quality of life and psychosocial function among patients with carcinoid tumours.: A longitudinal, prospective, and comparative study
Camilla Frojd et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Anatomic and functional imaging of metastatic carcinoid tumors
Andrew F. Scarsbrook et al.
RADIOGRAPHICS (2007)
Patient-reported outcomes in cancer: A review of recent research and policy initiatives
Joseph Lipscomb et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
Andrea Frilling et al.
SURGERY (2006)
Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors - A phase III study
Emilio Bajetta et al.
CANCER (2006)
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Ethan Basch et al.
LANCET ONCOLOGY (2006)
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
Endocrine pancreatic tumors: factors correlated with survival
P Tomassetti et al.
ANNALS OF ONCOLOGY (2005)
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors:: A randomized trial
R Arnold et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours
JM Zuetenhorst et al.
ENDOCRINE-RELATED CANCER (2004)
The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
JL Pasieka et al.
SURGERY (2004)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
JJM Teunissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
P Ruszniewski et al.
NEUROENDOCRINOLOGY (2004)
Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - Does HRQOL evaluation in prostate cancer research inform clinical decision making?
F Efficace et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Distress, quality of life and strategies to 'keep a good mood' in patients with carcinoid tumours: patient and staff perceptions
G Larsson et al.
EUROPEAN JOURNAL OF CANCER CARE (2003)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Perception of quality of life by patients, partners and treating physicians
KA Wilson et al.
QUALITY OF LIFE RESEARCH (2000)
Share Paper
